Day: March 26, 2026

Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25 Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to a leading centralized transplant rejection test Expect U.K. CE marking via self-certification in Q2 2026 Completed $26 million financing in February; funds intended to support expansion into heart transplantation market while also commercializing testing for kidneyNASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow shareholders, We are pleased to share that GraftAssureDx has become, to our knowledge, the first ever kitted dd-cfDNA assay to...

– Infrastructure: NYC and Western markets continue to demonstrate positive project momentum –– Life Sciences: R2 Secures 600‑System Commitment in China –– Spectrum: Recent network launches set to deliver benefits beginning in 2026 – NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) — INNOVATE Corp. (“INNOVATE” or the “Company”) (NYSE: VATE) announced today its consolidated results for the fourth quarter and full year ended December 31, 2025. Financial Summary(in millions, except per share amounts) Three Months Ended December 31,   Year Ended December 31,    2025       2024     Increase / (Decrease)     2025       2024     Increase / (Decrease)Revenue $ 382.7     $ 236.6     61.7 %   $ 1,246.0     $ 1,107.1     12.5 %Net loss attributable to common stockholders and participating preferred...

Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial HighlightsGenerated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarter Cyclo G6® product family revenue was $3.8 million, representing growth of 15% year-over-year compared to $3.3 million in the prior year quarterSold 15,900 Cyclo G6 probes compared to 13,300 in the prior...

Initiates fiscal 2026 guidance reflecting meaningfully improved profitability on modest sales growth driven by improvement at Tommy Bahama. Fiscal 2026 guidance includes revenues of $1.475 billion to $1.530 billion, GAAP EPS of $1.83 to $2.43 and adjusted EPS of $2.10 to $2.70; EPS expectations assume IEEPA tariff rates continued for balance of year. Increases quarterly dividend to $0.70 per share.ATLANTA, March 26, 2026 (GLOBE NEWSWIRE) — Oxford Industries, Inc. (NYSE:OXM) today announced financial results for its fourth quarter and full fiscal year 2025 ended January 31, 2026 and initiated guidance for the first quarter and full fiscal year 2026. Consolidated net sales in the fourth quarter of fiscal 2025 were $374 million compared to $391 million in the fourth quarter of fiscal 2024. Diluted loss per share on a GAAP basis...

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – – Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – – Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – – Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen – – Conference call today at 4:30 p.m. ET / 1:30 p.m. PT – SAN JOSE, Calif., March 26, 2026 (GLOBE NEWSWIRE) —...

SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) — CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent HighlightsFourth quarter 2025 revenue was $3.9 million, a 13% increase over the fourth quarter of 2024. Full year 2025 revenue was $13.6 million, a 15% increase compared to full year 2024. New accounts grew 16% in the fourth quarter of 2025 over the comparable quarter in 2024. Full year 2025 new accounts grew 21% compared to full year 2024. CapsoCam Plus® used by over 161,000 patients as of December 31, 2025. Submitted 510(k) application to the Food and Drug Administration (FDA) for its in-house developed AI-assisted module for...

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple sclerosis data underscore valuable pipeline-in-a-product opportunity with miv-cel Cash and cash equivalents of $279 million provide expected runway into 2028, funding SPS BLA filing, commercial launch, and Phase 3 gMG trial EMERYVILLE, Calif., March 26, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the fourth quarter and full year ended...

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women’s Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. “We are not a company that is just getting into women’s health. We are a women’s health biotech company – and we believe 2026 is the year investors will get to see what ten years of that commitment actually looks like. We built the company to change how women experience healthcare. That change...